Sakar Healthcare
SAKAR •NSE

Sakar Healthcare

₹1,028.6524.40 (2.43%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
998.85
Today’s high
1,059.70
52 week low
352.50
52 week high
1,229.85
Open price
1,024.00
Previous close
1,004.25
Live volume
1,66,071
Lower circuit
822.95
Upper circuit
1,234.35

Fundamentals

Market Cap
₹2,289Cr
ROE
12.39%
P/E Ratio(TTM)
53.38
EPS(TTM)
19.27
P/B Ratio
6.62
Dividend Yield
0.00%
Industry P/E
40.71
Book Value
155.50
Debt to Equity
0.13
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
SEP '26
₹87.70Cr
+17.70%
₹11.31Cr
+10.02%
0255075100
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue growthValue
1Y (TTM)+49%
3Y CAGR+23%
Profit growthValue
1Y (TTM)+149%
3Y CAGR+34%

About

Sakar Healthcare is a prominent player within India's pharmaceutical industry, distinguished by its vertically integrated manufacturing capabilities, particularly in the field of oncology. The company's vision is to become a global healthcare organization built on the three pillars of people, partnership, and performance to deliver world-class healthcare solutions. Its mission focuses on strengthening core competencies to be the preferred choice for partnerships and exploring new market opportunities to expand its product range. The company operates state-of-the-art facilities to produce both Active Pharmaceutical Ingredients (APIs) and finished formulations, ensuring quality control across the value chain. Its four manufacturing plants create a wide range of dosage forms, which include oral liquids, solids, injectables, and dry powder inhalers. With a strong export focus supported by a global distribution network, the company successfully serves customers in over 60 countries around the world.;
CEO/MD
Mr. Sanjay S. Shah
Founded in
2004
NSE symbol
SAKAR
Industry

Shareholding pattern

Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Shareholder details

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹2,502.50
+45.30 (1.84%)
L
    H
    19,010.9128.045.64
    PfizerPFIZER
    ₹3,917.90
    +14.10 (0.36%)
    L
      H
      17,930.5920.864.09
      ₹6,514.50
      +35.00 (0.54%)
      L
        H
        16,280.5091.6118.52
        Natco PharmaNATCOPHARM
        ₹804.35
        -0.70 (0.09%)
        L
          H
          15,772.8813.781.5
          Livesquawk •
          Sakar Healthcare reported Q2 revenue of 874M rupees, up from 576M rupees a year earlier. The company registered strong year-on-year revenue growth during the quarter.
          Livesquawk •
          Sakar Healthcare expands global oncology reach, securing 22 of 190 marketing authorizations and starting supplies from its EU GMP site. The company stated that the domestic price cap on oncology products will not impact its business outcomes.
          Livesquawk •
          Sakar Healthcare received 14 oncology product approvals in the EU, UK, and Canada. These approvals are supported by collaborations with 7 business partners.
          Livesquawk •
          Sakar Healthcare Q1 revenue surged 38% YoY to ₹730M vs ₹527M.
          2026
          23
          Oct
          Quarterly Result
          Release date
          24
          Jul
          Quarterly Result
          Release date
          12
          May
          Annual Result
          Release date
          5
          Feb
          Quarterly Result
          Release date
          2025
          7
          Nov
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks